What are the indications, dosing regimen, contraindications, common side effects, and alternative therapies for cilostazol in patients with intermittent claudication due to peripheral arterial disease?

Cilostazol for Intermittent Claudication

Cilostazol 100 mg orally twice daily is the first-line pharmacological therapy for improving symptoms and walking distance in patients with intermittent claudication due to peripheral arterial disease, provided they do not have heart failure of any severity. 1, 2, 3, 4, 5

Primary Indication

Cilostazol is indicated specifically for reducing symptoms of intermittent claudication and increasing walking distance in patients with lower extremity PAD 5. The drug improves maximal walking distance by 40-60% after 12-24 weeks of therapy 1, 2, 1.

Dosing Regimen

• Standard dose: 100 mg orally twice daily 1, 2, 3, 4
• Lower dose option: 50 mg twice daily (less effective than 100 mg) 1
• Duration for benefit assessment: Evaluate patient tolerance at 2-4 weeks and assess benefit within 3-6 months to determine if long-term therapy is warranted 4

Important dosing consideration: When cilostazol is coadministered with CYP3A4 inhibitors (erythromycin, diltiazem) or CYP2C19 inhibitors (omeprazole), dosage reduction should be considered 6.

Absolute Contraindication

Cilostazol must not be used in patients with heart failure of any severity 1, 2, 3, 4. This carries an FDA black-box warning because cilostazol is a phosphodiesterase type 3 inhibitor, and other drugs in this class (milrinone, vesnarinone) have been associated with increased mortality in heart failure patients 2.

Additional contraindications include:

• Severe hepatic impairment 6
• Severe renal impairment 6

Common Side Effects

The most frequently reported adverse effects include 2, 4:

• Headache (most common - occurs 2.83 times more often than placebo) 7
• Diarrhea
• Abnormal stools
• Palpitations
• Dizziness

These side effects are generally mild to moderate in intensity and often transient or resolve with symptomatic treatment (e.g., non-prescription analgesics) 6, 8. Approximately 20% of patients discontinue cilostazol within 3 months due to adverse effects 4.

Mechanism and Additional Benefits

Cilostazol is a phosphodiesterase type 3 inhibitor with vasodilator and platelet inhibitory properties 2. Beyond symptom improvement, it:

• Modestly increases ankle-brachial index (ABI), though hemodynamic effects don't fully explain claudication improvement 1
• Improves health-related quality of life 1, 7
• May reduce restenosis after femoropopliteal endovascular therapy 4, 9, 10
• Increases HDL cholesterol and decreases triglycerides 2

Alternative Therapies

Pentoxifylline (Second-Line)

Pentoxifylline 400 mg three times daily may be considered as second-line alternative therapy, though its clinical effectiveness is marginal and not well established 1, 2, 3. Meta-analyses show only marginal improvements in walking distance (21-48 meters increase in maximal walking distance) 2. Pentoxifylline does not increase ABI 1.

Supervised Exercise Training (First-Line Non-Pharmacological)

Supervised exercise training is highly effective and should be performed:

• Duration: 30-45 minutes per session
• Frequency: At least 3 times per week
• Minimum duration: 12 weeks
• Method: Walk until moderate claudication occurs, rest until symptoms resolve, then repeat 3

Critical pitfall: Informal "go home and walk" advice lacks evidence for efficacy; supervised programs in hospital or clinic settings are significantly more effective 2.

Ineffective Therapies (Class III - Do Not Use)

The following should NOT be used for intermittent claudication 1, 3, 4:

• Oral vasodilator prostaglandins (beraprost, iloprost)
• Vitamin E
• Chelation therapy (ethylenediaminetetraacetic acid) - may cause harmful adverse effects

Treatment Algorithm

1. Initial assessment: Confirm intermittent claudication due to PAD; screen for heart failure
2. If heart failure present: Cilostazol is contraindicated; proceed to supervised exercise and risk factor modification
3. If no heart failure:
   • Start cilostazol 100 mg twice daily
   • Assess tolerance at 2-4 weeks
   • Evaluate benefit at 3-6 months
   • Continue if beneficial; discontinue if no improvement
4. If cilostazol fails or is not tolerated: Consider pentoxifylline 400 mg three times daily (though benefit is marginal)
5. Concurrent therapy: All patients should receive supervised exercise training and cardiovascular risk reduction (antiplatelet therapy, statins) 3, 4

Safety Considerations

Cardiovascular mortality: In a Phase IV study of 1,439 patients followed for median 18 months, cardiovascular death occurred in 0.6% on cilostazol versus 0.5% on placebo, suggesting no increased mortality risk 5. However, the study stopped early due to enrollment difficulties.

Drug interactions: No clinically significant interactions with aspirin or warfarin regarding coagulation parameters 6. However, significant interactions occur with CYP3A4 and CYP2C19 inhibitors requiring dose adjustment 6.

Clinical Pearls

• Cilostazol should be considered in all patients with lifestyle-limiting claudication who lack heart failure 1, 2, 3
• The 100 mg twice daily dose is definitively more effective than 50 mg twice daily 1
• Benefits typically manifest within 2-4 weeks but may take up to 12-24 weeks for maximal effect 1, 5
• Recent evidence suggests potential benefit in preventing restenosis after femoropopliteal stenting, though this requires further validation 4, 9